Back to Search Start Over

SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response.

Authors :
Tsitsilonis OE
Paraskevis D
Lianidou E
Terpos E
Akalestos A
Pierros V
Kostaki EG
Kastritis E
Moutsatsou P
Politou M
Scorilas A
Sphicopoulos T
Thomaidis N
Trougakos IP
Tsakris A
Voulgaris N
Daskalaki CC
Evangelakou Z
Fouki C
Gianniou DD
Gumeni S
Kostopoulos IV
Manola MS
Orologas-Stavrou N
Panteli C
Papanagnou ED
Rousakis P
Sklirou AD
Smilkou S
Stergiopoulou D
Tsiodras S
Dimopoulos MA
Sfikakis PP
Source :
Vaccines [Vaccines (Basel)] 2021 Mar 02; Vol. 9 (3). Date of Electronic Publication: 2021 Mar 02.
Publication Year :
2021

Abstract

Between June and November 2020, we assessed plasma antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein in 4996 participants (aged 18-82 years, 34.5% men) from the National and Kapodistrian University of Athens. The weighted overall prevalence was 1.6% and monthly prevalence correlated with viral RNA-confirmed SARS-CoV-2 infections in Greece, in the same period. Notably, 49% of seropositive cases reported no history of SARS-CoV-2 infection-related clinical symptoms and 33% were unsuspected of their previous infection. Additionally, levels of anti-SARS-CoV-2 antibodies against the spike-protein receptor-binding domain were similar between symptomatic and asymptomatic individuals, irrespective of age and gender. Using Food and Drug Administration Emergency Use Authorization-approved assays, these results support the need for such studies on pandemic evaluation and highlight the development of robust humoral immune responses even among asymptomatic individuals. The high percentage of unsuspected/asymptomatic active cases, which may contribute to community transmission for more days than that of cases who are aware and self-isolate, underscores the necessity of measures across the population for the efficient control of the pandemic.

Details

Language :
English
ISSN :
2076-393X
Volume :
9
Issue :
3
Database :
MEDLINE
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
33801380
Full Text :
https://doi.org/10.3390/vaccines9030207